Noom

1.1 Identity & Business Model

Noom, Inc. (originally WorkSmart Labs, Inc.) is a consumer-first digital health company headquartered in New York, NY. Founded in 2008, the company employs a psychology-based approach to weight management, combining cognitive behavioral therapy (CBT) techniques with food logging, daily lessons, and human/AI coaching delivered through a mobile application. The company's revenue model is predominantly B2C subscription-based, with plans ranging from approximately $17–$70 per month depending on subscription length. Noom has expanded beyond its flagship Noom Weight product to include Noom Med (telehealth GLP-1 prescriptions plus coaching, launched May 2023), Noom Mood (stress/anxiety CBT program), and Noom DPP (CDC- recognized diabetes prevention program). The company also monetizes through Noom for Work, a B2B2C channel targeting employers and health plans. Noom was the first mobile application recognized by the CDC as a certified diabetes prevention program and has received multiple NIH grants validating its behavior-change methodology. A 2026 randomized clinical trial showed 4.1% body weight loss sustained at 68 weeks post-enrollment.[CO001, CO002, CO003, CO004, CO005, CO006]

1.2 Founders & Leadership

Noom was co-founded in 2008 by Saeju Jeong and Artem Petakov. Jeong, born in South Korea to a family of physicians, was inspired by his father's vision of transforming sick care into preventive care. He served as CEO from founding through July 2023, when he transitioned to Executive Chairman as part of a planned succession. Artem Petakov, the technical co- founder, serves as President and oversees product and engineering. In July 2023, Geoff Cook was appointed CEO; Cook previously founded and led The Meet Group through its IPO and subsequent acquisition, bringing consumer-tech scaling experience. The leadership transition signaled a shift from founder-led growth to professional operational management at a time when the company was navigating post-COVID subscriber declines and the GLP-1 market disruption. Public governance disclosure remains limited—no complete board roster or ownership breakdown has been published in reviewed sources, leaving key-person concentration and governance structure as open diligence issues.[CO009, CO010, CO011, CO012, CO013, CO014]

1.3 Funding & Capital Formation

Noom's largest fundraise was its May 2021 Series F round of $540M led by Silver Lake, which valued the company at $3.7B post-money. Other Series F participants included Oak HC/FT, Temasek, Novo Holdings, Sequoia Capital, RRE Ventures, and Samsung Ventures. Earlier rounds include a ~$58M Series E in 2019 (Sequoia, Samsung, RRE) and multiple earlier seed through Series D rounds. Total disclosed capital raised is approximately $643M (range $578M–$669M across trackers like Crunchbase, Tracxn, and Sacra). No debt facilities or credit lines have been identified in reviewed public sources. As of Q2 2026, secondary-market implied valuation has dropped to approximately $720M—a ~77% discount to the 2021 peak—reflecting post-COVID subscriber declines, the GLP-1 market disruption, and broader late-stage private market corrections. Over $272M in secondary bids and offers were logged in the 90 days prior to April 2026, suggesting ongoing liquidity interest despite the markdown.[CO016, CO017, CO018, CO019, CO020, CO021]

1.4 Scale & Key Metrics

Noom reports 50M+ cumulative registered users since founding. Peak paying subscribers reached approximately 5M during the 2020–2021 COVID-driven digital health surge, but have declined since; recent estimates suggest low single-digit millions of active subscribers. Revenue peaked at an estimated ~$400M in 2021, coinciding with maximum subscriber density. Headcount reached ~3,400 at peak and currently stands at approximately 2,500 after multiple restructuring rounds. The company has undergone at least four rounds of layoffs between 2022 and 2025, primarily affecting its human coaching staff as the model shifted toward AI- augmented and medication-focused offerings. Material metrics that remain undisclosed in public sources include exact current revenue, ARR, gross margin, net revenue retention, and customer acquisition cost—leaving an incomplete picture of unit economics and financial trajectory.[CO025, CO026, CO027, CO028, CO029, CO030]

1.5 Adverse Events & Risk Flags

In 2022, Noom agreed to a $62M class-action settlement ($56M cash plus $6M in subscription credits) resolving allegations of deceptive auto-renewal practices and dark-pattern cancellation barriers. The settlement required Noom to implement self-service cancellation, explicit consent checkboxes for auto-renewal, and clearer disclosure of subscription terms. This aligns with the FTC's broader "Click-to-Cancel" enforcement trend. Between 2022 and 2025, the company executed approximately 20% workforce reductions, with coaching staff disproportionately affected as the business model shifted away from human-intensive coaching toward AI and medication management. The GLP-1 market disruption (Wegovy, Ozempic, Zepbound) simultaneously cannibalized traditional behavioral weight-loss demand and created a new opportunity that Noom is pursuing through Noom Med. High B2C subscription churn remains a structural risk inherent to the weight-loss category. In April 2026, Noom acquired Tailor Made Compounding as its first major M&A, expanding into healthy aging and compounded peptides— a segment facing FDA regulatory scrutiny.[CO033, CO034, CO035, CO036, CO037, CO038]

1.6 Exhibits

2.1 Market Boundary and Definition

Noom's addressable market straddles several overlapping spending categories. The core market is consumer-facing digital weight management and behavior-change apps — a segment Mordor Intelligence sizes at $1.29 billion globally in 2026, growing at 16.9% CAGR to $2.83 billion by 2031. The broader digital health for obesity ecosystem, which includes wearable devices, telehealth platforms, AI coaching tools, and digital therapeutics, is valued between $78 billion and $99 billion in 2026 depending on the source and scope definition. Noom's expansion into Noom Med (telehealth-based GLP-1 prescriptions) places it partly in the U.S. telehealth market ($64–65B in 2026) and adjacent to the massive GLP-1 pharmaceutical market ($73B+ in 2026). The corporate wellness and employer health benefits channel ($66–72B in 2026) represents Noom's B2B2C opportunity through Noom for Work. Excluded spend includes purely pharmaceutical manufacturing, hospital-based bariatric surgery, in-person gym memberships without digital integration, and pure-play medical device companies. The market boundary matters because Noom's revenue model — B2C subscription plus B2B employer licensing plus telehealth medication management — means its addressable slice is meaningfully smaller than any single headline market figure.[CM001, CM002, CM003, CM004, CM005, CM006]

2.2 Market Sizing (TAM/SAM/SOM)

Multiple analyst lenses produce dramatically different market sizes depending on boundary choices. The broadest framing is the global weight loss and obesity management market at approximately $279 billion in 2026 (Research and Markets), which includes pharma, surgery, services, and digital tools. The digital health for obesity segment ranges from $78 billion (VPA Research, Fortune Business Insights) to $99 billion (The Business Research Company), reflecting different inclusion of hardware, wearables, and telehealth platforms. Noom's most direct competitive segment — exercise and weight loss apps — is far narrower at $1.29 billion (Mordor Intelligence) to $1.39 billion (Coherent Market Insights) in 2026. A reasonable SAM for Noom would combine the U.S. share of weight loss apps (approximately $500M given North America's 40% share) plus the addressable U.S. telehealth obesity slice and employer wellness digital spending. The SOM remains unclear because Noom does not disclose current revenue; its peak revenue was estimated at approximately $400 million in 2021 but has declined since. This boundary sensitivity — from $1.3B to $99B depending on scope — is the core sizing lesson for diligence. The GLP-1 pharmaceutical market ($73.4B in 2026, projected to exceed $100B by 2030 per Goldman Sachs estimates cited in Becker's) is adjacent rather than directly addressable by Noom, but Noom Med's telehealth prescribing model captures a medication-management and coaching overlay fee on that pharmaceutical spend.[CM010, CM011, CM012, CM013, CM014, CM015]

2.3 Buyer/User/Payer Segmentation

Noom serves three distinct buyer-payer configurations. In the B2C channel, the individual consumer is both buyer and payer, purchasing monthly or annual subscriptions typically ranging from $17–$59 per month. The user is the individual seeking weight loss or health behavior change, motivated by personal health goals, physician recommendation, or GLP-1 medication support. In the B2B2C employer channel (Noom for Work), the buyer is the HR/benefits decision-maker, the payer is the employer or health plan, and users are enrolled employees and dependents. Corporate wellness budgets are the funding source, with adoption triggered by rising healthcare costs, chronic disease prevalence, and productivity goals. In the Noom Med telehealth channel, the buyer-user is the individual patient seeking GLP-1 prescriptions and coaching support, with payment split between the consumer (subscription fee) and potentially insurance or employer coverage for the medication itself. The U.S. dominates Noom's market given North America's 40% share of both the exercise/weight loss app and corporate wellness markets. Large employers (500+ employees) are the primary B2B targets, as 76% of employees at such organizations have access to wellness programs according to the U.S. Department of Labor.[CM020, CM021, CM022, CM023, CM024, CM025]

2.4 Growth Drivers and Adoption Constraints

The most powerful growth driver is the global obesity epidemic: 40.3% of U.S. adults have obesity (CDC/NHANES 2021–2023 data), and WHO reports over 1 billion people globally living with obesity as of 2022, with prevalence rising in nearly every country. This structural demand floor ensures sustained need for weight management solutions. The GLP-1 revolution simultaneously creates both opportunity and threat: GLP-1 drugs like Wegovy and Zepbound deliver 15–22% mean weight loss in trials, far exceeding behavioral-only programs, which drove approximately 12 million U.S. adults onto GLP-1 medications by end of 2026. For Noom, this creates opportunity through Noom Med (medication management plus coaching) but also devastating substitution risk for the core behavioral subscription product. Additional drivers include rising smartphone penetration, employer demand for preventive digital health solutions, AI-powered personalization, and expanded Medicare GLP-1 coverage beginning July 2026 at $245/month with $50 copay. Key constraints include high consumer churn typical of weight-loss subscriptions, the perception that medication makes behavioral apps obsolete, intense competition from telehealth-first GLP-1 providers (Hims, Ro, Found), FTC regulatory scrutiny over subscription practices, and price sensitivity in the consumer health app market where freemium models dominate (67% market share per Mordor Intelligence).[CM027, CM028, CM029, CM030, CM031, CM032]

2.5 Sizing Gaps and Contradictions

The most material sizing gap is Noom's own revenue trajectory. Peak revenue was estimated at $400M in 2021 during the COVID-driven subscription surge, but current revenue is undisclosed and widely believed to have declined significantly alongside subscriber attrition post-2021. Without current revenue, subscriber count, or churn rate disclosure, SOM calculations are speculative. A second contradiction is the wide divergence among analyst estimates: digital health for obesity ranges from $71.67B (InsightAce) to $99.36B (TBRC) for 2026 depending on what hardware, wearables, and telehealth platforms are included — a 39% spread that reflects definitional rather than analytical disagreement. Third, the GLP-1 market's effect on behavioral app demand is unclear: WeightWatchers' bankruptcy (revenue fell to $811M in 2024 with subscription revenues declining 5.6%) demonstrates catastrophic disruption, yet the digital health for obesity market overall continues growing at 22–26% CAGR because GLP-1 companion digital tools and telehealth obesity platforms are expanding even as standalone behavioral programs shrink. This means Noom's pivot to Noom Med may position it in the growing subsegment rather than the declining one, but execution risk is high and the company competes against well-capitalized telehealth GLP-1 providers.[CM039, CM040, CM041, CM042, CM043, CM044]

2.6 Exhibits

3.1 Competitive Landscape Overview

Noom competes across four overlapping competitor clusters rather than a single peer set. First are direct behavioral and calorie-tracking app competitors—MyFitnessPal, Lose It!, and Lifesum—which compete on food logging, database breadth, and freemium pricing without behavioral coaching depth. Second are GLP-1 telehealth challengers—Hims & Hers (NYSE: HIMS), Ro, Found, and Calibrate—that offer medication-first weight loss with telehealth prescriptions and pharmacy-integrated delivery, increasingly encroaching on Noom's GLP-1 hybrid positioning. Third are enterprise-grade digital therapeutics platforms—Omada Health and Teladoc/Livongo—that sell B2B2C chronic condition management programs to employers and health plans. Fourth is the legacy incumbent WeightWatchers, which emerged from Chapter 11 bankruptcy in June 2025 after eliminating $1.15 billion in debt and is now aggressively expanding its own telehealth clinical business with 57% year-over-year clinical revenue growth. The competitive pressure is asymmetric: medication-first platforms can replicate behavioral features more easily than Noom can replicate vertically integrated pharmacy economics.[CP001, CP002, CP003, CP004, CP005, CP006]

3.2 Direct Behavioral and App Competitors

MyFitnessPal remains the largest competitor by registered user base with over 220 million accounts and 30 million monthly active users, generating approximately $310 million in revenue under Francisco Partners ownership. Its strength is the world's largest food database and calorie-tracking simplicity, but it lacks Noom's behavioral coaching depth and has no GLP-1 clinical offering. Lifesum competes on AI-powered meal planning and personalized nutrition with a freemium model that undercuts Noom's premium pricing. Lose It! offers straightforward calorie counting with barcode scanning and AI photo recognition at lower price points. WeightWatchers, despite its Chapter 11 filing in May 2025, continues to serve over 3 million members globally and reported 57% clinical revenue growth in Q1 2025 through its WeightWatchers Clinic telehealth offering. After exiting bankruptcy in June 2025 with only $465 million in remaining debt (down from $1.6 billion), WW is investing in digital transformation and GLP-1 prescriptions. These app-based competitors generally lack Noom's psychology-driven coaching methodology but compete effectively on price, simplicity, and database breadth—and several are now adding GLP-1 access or AI-powered features.[CP011, CP012, CP013, CP014, CP015, CP016]

3.3 GLP-1 Telehealth Challengers

The most acute competitive threat to Noom comes from medication-first telehealth platforms that have rapidly scaled GLP-1 weight loss programs. Hims & Hers Health is the largest by revenue, reporting $608 million in Q1 2026 revenue (up 4% year-over-year) with 2.6 million subscribers, and raising full-year 2026 guidance to $2.8–$3.0 billion. The company made a strategic pivot from compounded to branded GLP-1 medications (partnering with Novo Nordisk for Wegovy), though this transition caused a $92 million Q1 2026 net loss from restructuring charges. Ro has raised approximately $1 billion in total funding at a $7 billion valuation (February 2022), with estimated $598 million in 2024 revenue and GLP-1 offerings accounting for roughly 40% of revenue. Ro's competitive advantage is its vertically integrated pharmacy infrastructure enabling lower medication costs. Found (joinfound.com) offers personalized GLP-1 programs with both branded Wegovy/Zepbound and compounded alternatives, competing on affordability and insurance coverage. Calibrate has raised approximately $128 million and positions itself as an outcomes-based metabolic health platform combining GLP-1 prescriptions with one-on-one video physician visits and coaching. These medication-first platforms threaten Noom because they can offer GLP-1 access at lower price points with simpler operational models, while Noom's behavioral coaching adds cost that price-sensitive consumers may not value.[CP020, CP021, CP022, CP023, CP024, CP025]

3.4 Competitive Positioning and Moat

Noom's differentiation rests on its psychology-based behavioral change methodology—rooted in cognitive behavioral therapy—combined with GLP-1 medication access through Noom Med. The company's largest internal analysis showed that GLP-1 members in the top engagement quartile achieved over 25% more weight loss at 40 weeks, and members on the Microdose GLP-1Rx Program showed 77.8% four-week retention rates—reportedly 10 times higher than average health app retention. Noom's 50 million cumulative registered users provide a massive dataset for AI personalization, and its B2B2C channel (Noom for Work) gives it employer and health plan distribution that pure DTC competitors lack. However, Noom's moat is narrowing. The behavioral coaching model is costly to scale (even with AI replacing some human coaches), and competitors like Omada Health—which reported $78 million Q1 2026 revenue (up 42% year-over-year) with 1.02 million members and partnerships with all three major PBMs—are building similar hybrid clinical-plus-behavioral offerings with stronger payer infrastructure. Omada's new partnership with Eli Lilly's Employer Connect program gives it a direct employer GLP-1 channel that Noom does not yet match.[CP031, CP032, CP033, CP034, CP035, CP036]

3.5 Threats and Disadvantages

Noom faces three structural competitive disadvantages. First, high churn: B2C weight-loss subscriptions suffer inherently high attrition, and GLP-1 discontinuation data shows 64–84% of non-diabetic patients stop medication within two years, creating risk that app engagement drops when medication stops. Second, pharmacy economics disadvantage: vertically integrated competitors like Ro control their medication supply chain, enabling lower per-unit costs that Noom cannot match without building or acquiring pharmacy infrastructure. Third, pricing pressure: Noom Med's Microdose GLP-1Rx starts at $79 then $199/month, while pure medication-first competitors offer compounded semaglutide from $99/month. The broader market is also experiencing rapid commoditization as generic and compounded GLP-1s proliferate, squeezing margins for all players. Additionally, Noom's secondary- market valuation has declined approximately 77% from its 2021 peak of $3.7 billion to roughly $720 million in Q2 2026, reflecting investor skepticism about its competitive positioning relative to medication-first platforms with clearer pharmacy economics and faster revenue scaling.[CP040, CP041, CP042, CP043, CP044, CP045]

3.6 Exhibits

4.1 Revenue & Growth

Noom's revenue trajectory reflects an aggressive consumer subscription growth story punctuated by a COVID-era surge and a subsequent pivot to GLP-1 telehealth. Third-party analyst Sacra estimates Noom hit $1B in ARR by end-2023, growing 25% year-over-year with approximately 1.5 million paying subscribers. Earlier estimates from MobileMarketingReads placed 2020 revenue at approximately $400M (nearly double 2019's ~$237M) and 2021 revenue at ~$600M. Other trackers such as GrowJo and TechList cite a 2026 revenue estimate of ~$296M, while IncFact estimates over $500M—illustrating the wide confidence intervals around a private company with no audited disclosures. Noom's revenue is primarily subscription-based: the core Noom Weight app charges $17–$70 per month depending on plan length, while the newer Noom Med GLP-1 programs range from $99 to $279 per month inclusive of medication. In February 2025, Noom disclosed that its GLP-1 Rx and pill-based medication programs together reached a $100M revenue run-rate within four months of their September 2024 launch. This suggests a rapid revenue mix shift toward higher-ARPU medical products, though the sustainability of that growth rate and its margin profile remain undisclosed. The discrepancy between the Sacra $1B ARR estimate and the canonical $400M peak figure likely reflects different measurement periods, methodologies, and product scope; we use the canonical ~$400M (2021 peak) as the conservative anchor and note the Sacra figure as a higher-bound third-party estimate.[CI001, CI002, CI003, CI004, CI005, CI006]

4.2 Subscription Unit Economics

Noom's unit economics are partially inferrable from public pricing and industry benchmarks but fundamentally undisclosed. List pricing for Noom Weight ranges from $17.42/month on a 12-month commitment to $70/month on a rolling monthly plan. Noom Med GLP-1 programs command significantly higher prices: the Microdose GLP-1Rx plan is $199/month and the Full-Dose plan is $279/month, both inclusive of compounded medication. This pricing shift implies materially higher ARPU but also higher COGS given medication fulfillment costs. Sacra reports that Noom employs an LLM-powered chatbot for initial interactions, creating leverage for human coaches paid $19–$24/hour who manage 300–400 users each. Industry subscription benchmarks suggest average monthly churn of ~5.3% for wellness subscriptions, implying average subscriber lifetimes of roughly 19 months. Noom's own engagement data shows 40% D30 retention for Microdose GLP-1Rx members—10x the digital health app average—and 77% still engaged at week four. Ad spend scaled from $5M in 2017 to an estimated $330M in 2023, suggesting CAC has been extremely high relative to subscription LTV unless retention substantially exceeds industry norms. The $56M dark-pattern class-action settlement in 2022 hints that a meaningful portion of historical revenue may have been generated through friction-based retention rather than genuine product engagement. Without disclosed CAC, LTV, gross margin, or net revenue retention, the true unit economics remain a material evidence gap.[CI010, CI011, CI012, CI013, CI014, CI015]

4.3 Profitability, Burn & Runway

Noom has never publicly disclosed profitability, operating margins, burn rate, or cash position. However, several signals suggest the company has undergone significant cost restructuring. In 2022, Noom executed at least two rounds of layoffs: first cutting approximately 25% of its coaching staff in April 2022 as part of an AI-coaching model shift, then reducing a further ~10% of total workforce (roughly 500 employees) in October 2022. MobiHealthNews reported in early 2025 that additional layoffs occurred as part of a "revenue mix shift" toward GLP-1 products. The company's stated rationale—building "a more efficient business"—implies that prior unit economics were unsustainable at the existing cost structure. The 2022 leadership transition from founder-CEO Saeju Jeong to Geoff Cook (a CEO with a track record of driving profitability at The Meet Group) further signals a board-level pivot from growth-at-all-costs to unit-economics discipline. Ad spend of $330M in 2023 against even $1B ARR implies a 33% sales-and-marketing-to-revenue ratio before accounting for coaching staff, technology, and G&A—making profitability unlikely without the restructuring. The acquisition of Tailor Made Compounding pharmacy in April 2026 adds vertical integration but also capital intensity. Without audited financials, the path to profitability remains a thesis rather than a demonstrated fact.[CI019, CI020, CI021, CI022, CI023, CI024]

4.4 Capital Structure & Funding

Noom has raised approximately $643M in cumulative funding, though tracker estimates range from $578M (Tracxn's earlier figure of $624M) to $669M (TechStackIPO) and $670M (FormBlends). The company's funding history spans at least 10–15 rounds since founding in 2008, with the transformative event being the May 2021 Series F of approximately $540M led by Silver Lake at a $3.7B post-money valuation. Other Series F participants included Oak HC/FT, Temasek, Novo Holdings, Sequoia Capital, RRE Ventures, and Samsung Ventures. Silver Lake's press release noted that a portion of capital was used for share repurchases. PremierAlts reports a Later Stage VC round in April 2025 (amount undisclosed) and total funding of $668.8M. On the secondary market, PM Insights data shows Noom's implied valuation fell to approximately $720M by Q2 2026—a 77%+ discount to the 2021 peak. The SEC EDGAR records confirm Noom (formerly WorkSmart Labs, Inc.) filed a Form D notice of exempt offering in January 2015, with CIK 0001595910. UK Companies House records for Noom Health UK Limited (company 13453588) show accounts filed as a small company through January 2025, indicating limited UK subsidiary scale. The wide range in total-raised figures ($578M–$669M) constitutes a data conflict that cannot be resolved without cap-table access; the canonical figure of ~$643M represents a mid-range consensus.[CI027, CI028, CI029, CI030, CI031, CI032]

4.5 Financial Risks & Disclosure Gaps

The single largest financial risk for any prospective investor or acquirer is the near-total absence of audited financial disclosure. Noom is a late-stage private company with a peak valuation of $3.7B, thousands of employees, and an estimated revenue base in the hundreds of millions, yet it discloses neither revenue, margins, cash, burn, retention, nor unit economics publicly. The secondary-market discount of ~77% from peak valuation implies that institutional investors have repriced the equity significantly—either reflecting genuine business deterioration or simply the broad late-stage private markdown of 2022–2024. Additional risks include: (1) revenue quality uncertainty given the $56M dark-pattern settlement and high churn typical of B2C weight-loss subscriptions; (2) the GLP-1 medication pivot introduces pharmacy fulfillment and regulatory complexity alongside higher ARPU; (3) competitive pressure from Hims & Hers, Ro, and vertical GLP-1 entrants who may undercut on price; (4) the absence of any IPO filing (S-1) despite reaching scale suggests either the financials do not support public-market scrutiny or the company is not yet profitable. The TechStackIPO readiness score of 64/100 (Grade C) corroborates moderate but not high IPO preparedness. For diligence purposes, every material financial metric remains a private-evidence-only gap requiring management data-room access.[CI034, CI035, CI036, CI037, CI038, CI041]

4.6 Exhibits

5.1 Product Portfolio & Core Experience

Noom operates a multi-product digital health platform serving consumers directly (B2C) and through employers and health plans (B2B2C). The flagship product, Noom Weight, delivers a psychology-based weight management program through daily CBT-informed lessons, AI-powered food logging with a database of over one million items, color-coded calorie-density guidance (green, yellow, orange), step tracking with gamification rewards, personalized coaching, and peer support communities called Circles. The platform has served over 50 million registered users since launch. Noom Med, launched in May 2023, adds telehealth GLP-1 prescribing (semaglutide and tirzepatide) with integrated behavioral support, requiring participation in the behavioral program alongside medication. Noom expanded to a Microdose GLP-1Rx Program in 2025, offering compounded lower-dose semaglutide at $79 initial plus $199/month. Additional products include Noom Mood for stress and anxiety management using CBT, Noom Diabetes Prevention Program (first CDC-recognized mobile DPP), Noom + HRT for menopause management, and Noom Move with over 1,000 fitness classes. The enterprise arm, Noom for Work (launched 2022), provides employer and health-plan access to these programs, with Highmark deploying to nearly 2 million eligible members beginning January 2026. Pricing ranges from $17.42/month for annual Noom Weight plans to $349/month for full-dose GLP-1Rx programs including medication, all FSA/HSA eligible.[CE001, CE002, CE003, CE004, CE005, CE006]

5.2 Behavioral/Coaching Methodology & Clinical Evidence

Noom's differentiation rests on a psychology-first methodology drawn from cognitive behavioral therapy (CBT), motivational interviewing, and habit formation science. The curriculum delivers daily 10-minute bite-sized lessons through articles and quizzes, targeting the psychological drivers of eating behavior rather than imposing food restrictions. The coaching model operates as a human-plus-AI hybrid: Welli, the AI chatbot launched in June 2024, provides 24/7 on-demand guidance while human goal specialists handle accountability and relationship building via direct messaging. Clinical evidence supports the approach across multiple studies. The 2016 Scientific Reports retrospective study (n=35,921) showed 77.9% of users achieved weight loss, with engagement frequency as the strongest predictor. The 2026 randomized controlled trial published in Obesity Science & Practice (n=427) demonstrated sustained weight loss of 4.1% body weight at 68 weeks—continuing to deepen for a full year after the 16-week active program ended—compared with 1.5% weight gain in the control group (p<0.001). Noom members were more than twice as likely to achieve clinically significant weight loss of at least 5% (41% vs 19.5%). For GLP-1 users, a January 2026 analysis of 14,210 subscribers showed the most-engaged quartile lost 25.2% more weight (8.3 additional lbs) at week 40 than the least-engaged, and persisted 2.2x longer on their medication program. However, independent reviewers note that most Noom studies are observational or company-funded, long-term data beyond 68 weeks remains limited, and dropout rates are high—typical of B2C weight-loss apps.[CE011, CE012, CE013, CE014, CE015, CE016]

5.3 Noom Med & GLP-1 Telehealth Stack

Noom Med represents the company's strategic pivot to address the GLP-1 weight-loss medication market. The workflow begins with an online health assessment, followed by clinical review by a licensed physician or nurse practitioner. Eligible patients (BMI ≥30 or ≥27 with comorbidity) receive a prescription, and compounded semaglutide or tirzepatide is shipped directly within approximately 7 days. The program uniquely requires ongoing participation in Noom's behavioral change platform—there is no medication-only option. Plan tiers in 2026 include Telehealth Only ($99/month for brand-name Rx with own pharmacy), Microdose GLP-1Rx ($79 start then $199/month including compounded medication), and Full GLP-1Rx ($279-$349/month). The GLP-1 Companion app integrates medication tracking, side-effect support, Muscle Defense guidance for lean mass preservation, AI-powered body composition scans, glucose curve forecasting, and gamification. Key engagement metrics show 77.8% of Microdose users engaged for 4+ weeks and D30 engagement above 40%—claimed to be 10x average health app retention. The legal landscape is uncertain: Noom sells compounded semaglutide under Section 503A exceptions after the FDA removed it from the shortage list, and Novo Nordisk/Eli Lilly are challenging compounders in court. This represents a material regulatory risk to Noom Med revenue.[CE004, CE005, CE020, CE022, CE023, CE024]

5.4 AI/ML & Technology Architecture

Noom's technology platform is built on a microservices architecture deployed on AWS, with native mobile apps for iOS (Swift) and Android (Kotlin), and a React.js web interface. The backend uses Python (Django) with PostgreSQL as the primary database, Redis for caching, and Kubernetes (EKS) for container orchestration. The AI/ML layer includes several customer-facing features: AI food logging via photo recognition, text, and voice input (launched June 2024); Welli, the GPT-powered personal health assistant trained on Noom-specific data; AI-powered body composition face and body scans (launched 2025); glucose curve forecasting; and algorithmic personalization of lesson content and coaching interventions. On the data engineering side, the platform processes engagement, weight, nutrition, and activity data through pipelines feeding analytics and ML model training. Noom's GitHub organization shows 41 public repositories—primarily forks, workflow actions (branch-cleanup-action), and utility tools rather than substantial open-source frameworks, indicating an engineering organization that is internal-facing. Job postings reveal use of GraphQL, RabbitMQ/SQS message queues, Terraform infrastructure-as-code, and CI/CD via GitHub Actions. The company maintains offices in New York City and Princeton, NJ, with a remote-first engineering culture. The AI team was built by data scientists and ML engineers specifically versed in digital healthcare, according to CPO Aaron Severs.[CE029, CE030, CE031, CE032, CE033, CE034]

5.5 Data Security, Compliance & Product Risks

Noom handles protected health information (PHI) through its coaching, telehealth, and medication programs, requiring HIPAA compliance. The company operates under Business Associate Agreements with vendors, encrypts data at rest (AES-256 via AWS KMS) and in transit (TLS 1.2+), and implements role-based access controls. Noom received multiple NIH grants and was the first mobile app to achieve CDC recognition as a certified Diabetes Prevention Program—a meaningful quality signal. However, public security documentation is notably thin: no SOC 2 report, no public security whitepaper, no status page, and no penetration testing disclosure have been identified in the reviewed evidence. Product risks are material and multi-dimensional. Coaching quality is a persistent complaint—Trustpilot and app reviews cite bot-like responses, impersonal coaching, and gap between marketing promise and delivered experience. The $56 million class-action settlement (February 2022) for dark-pattern auto-renewal practices damaged trust and required enhanced cancellation disclosures. GLP-1 compounding faces legal challenge from Novo Nordisk and Eli Lilly, threatening Noom Med's supply chain. High churn is structurally inherent in B2C weight-loss subscriptions. The shift from human coaches to AI (following 2022-2023 layoffs reducing headcount from ~3,400 to ~2,500) represents both an efficiency gain and a quality risk that reviewers consistently flag. App store ratings remain strong (4.7 iOS from 730K+ reviews; 4.1 Android from 315K+ reviews), but the gap between aggregate scores and vocal complaint patterns suggests polarized user experiences.[CE036, CE037, CE038, CE039, CE040, CE041]

5.6 Exhibits

6.1 Customer Base and Segmentation

Noom's customer base divides into two principal channels. The dominant B2C direct-to-consumer segment comprises individual subscribers who discover Noom through paid social ads (primarily Meta, TikTok, YouTube) and convert through the company's signature 40-100 question onboarding quiz funnel. The smaller but growing B2B2C channel, branded Noom Health (formerly Noom for Work), distributes Noom Weight, Noom Med, Noom Diabetes Prevention, and GLP-1 Companion programs through employer health plans and benefits administrators. Noom claims to offer programs to "millions of covered lives" through this enterprise arm. Within B2C, demographic data from SimilarWeb and Noom's own company overview documents indicate the audience skews approximately 70% female and 30% male, with the largest age cohort being 45-54 years old. Noom has stated it has welcomed over 8 million women ages 40-60 into its programs. Geographic concentration is heavily US-centric, with roughly 80% of web traffic originating domestically, followed by Canada, UK, and Australia. The cumulative registered user base exceeds 50 million, but the paying subscriber count peaked at approximately 5 million during the 2020-2021 COVID surge and has since declined to low single-digit millions. This gap between registered and paying users reflects both the free-trial funnel architecture and the high churn inherent to consumer weight-loss subscriptions. [CU001, CU002, CU003, CU004, CU005, CU006]

6.2 B2C Subscriber Economics and Demographics

Noom's B2C model charges monthly subscription fees ranging from $70/month (monthly plan) to $17.42/month (annual plan at $209/year). The Noom Med clinical program with GLP-1 prescriptions carries additional costs. Pricing has increased steadily, with users reporting renewal at higher rates than initial promotional offers. Revenue peaked at approximately $400 million in 2021 during COVID-driven demand, with estimates suggesting a decline to roughly $296 million by 2025-2026. The typical Noom subscriber is a US-based woman aged 35-54 seeking sustainable behavior-change-based weight loss rather than restrictive dieting. Psychographic fit emphasizes emotional eaters, yo-yo dieters, and those seeking structured psychological support. Noom's published clinical data reports 78% of users lose weight and 56% achieve at least 5% body weight loss within six months, per a study in JMIR mHealth. The largest-ever Noom RCT (427 adults, published June 2026 in Obesity Science & Practice) showed members lost an average 4.1% body weight by week 68, with weight loss continuing for a full year after the 16-week program ended. These outcome metrics are notable but reflect engaged completers rather than all subscribers, and the company does not publicly disclose churn-adjusted completion rates or lifetime value by cohort. [CU008, CU009, CU010, CU011, CU012, CU013]

6.3 B2B Employer and Payer Channel

Noom Health, the enterprise division, has accelerated B2B partnerships since 2023. The most significant announced partnership is with Highmark Health, which beginning January 2026 offers customized Noom Weight Management journeys to nearly 2 million eligible commercial plan members across Pennsylvania, West Virginia, Delaware, and New York. Highmark described the launch as "one of the most successful new solutions we've ever offered." Other verified B2B partners include Collective Health (joint Noom Med with SmartRx offering for employers, announced March 2025), Waltz Health (GLP-1 affordability and fulfillment for employers), Navitus Health Solutions (Noom Weight, DPP, and Mood programs for 11M+ covered lives, October 2023), Castlight Health (navigation platform integration), and Personify Health (enterprise marketplace certification). Noom's Personify Health listing claims 25% average employee enrollment rate and 40% of engaged users losing 5%+ body weight. Collective Health estimates 28% potential savings for employers covering GLP-1 drugs through the joint program. The B2B channel addresses employer demand for cost-effective obesity management amid soaring GLP-1 medication costs, but revenue contribution from B2B relative to B2C remains undisclosed. The channel is strategically critical as it provides more predictable multi-year contract revenue versus volatile consumer subscriptions. [CU015, CU016, CU017, CU018, CU019, CU020]

6.4 Acquisition and Retention Dynamics

Noom's acquisition engine centers on one of consumer health's most studied conversion funnels. The onboarding quiz spans 40-113 screens and takes 10-15 minutes, employing progressive commitment psychology, personalization theater (projected weight-loss timelines and custom plans), and strategic price anchoring. Industry observers estimate quiz-to-paid conversion exceeds 10% of quiz completers, versus a 2.7% median day-zero conversion for subscription health apps. A significant portion of paid acquisition routes through web-based funnels rather than app stores, enabling faster iteration and avoiding platform commissions—one analysis estimated the DTC web portal generated 42% of new subscriptions. Paid social (Meta, TikTok, YouTube) is the primary channel, supplemented by affiliate/influencer marketing (e.g., partnership with The Independent drove top-3 partner status in UK) and Google search. Retention is the structural challenge. Industry benchmarks show 30-day retention for health/fitness apps averages 8-12%. Noom's GLP-1 Companion program reports significantly higher metrics: 77.8% of Microdose GLP-1Rx users stayed engaged for 4+ weeks, and D30 engagement was 43.6% (10x industry average). However, a third-party study of 35,000 Noom switchers found 62.4% churned within six months, with average prior spend of $419 before cancellation. The top reason for leaving was "psychology lessons feeling repetitive" (34.2%). Noom does not publicly disclose aggregate churn rates, NRR, or cohort retention curves. [CU023, CU024, CU025, CU026, CU027, CU028]

6.5 Satisfaction, Reviews, and Complaints

Noom receives mixed but generally positive app store ratings: 4.7/5 on the Apple App Store (860,000+ ratings) and 4.1/5 on Google Play (314,000+ reviews, 10M+ downloads). Professional review scores range from 7.2/10 to 9/10 in 2026 evaluations. However, consumer complaint platforms reveal persistent issues. Trustpilot hosts 66,000+ reviews with significant negative sentiment around billing and cancellation. The Better Business Bureau received 1,200+ complaints leading to a past "D" rating, though the company has since improved some practices. ComplaintsBoard and PissedConsumer show recurring patterns: surprise charges, difficult cancellations, unresponsive customer service, and bot-like coaching. The most significant adverse event was the 2022 $62M class-action settlement ($56M cash + $6M credits) covering approximately 2 million users who purchased auto-renewing subscriptions between May 2016 and October 2020. The lawsuit alleged Noom made cancellation "difficult by design," with a former engineer quoted confirming intentional friction. Settlement reforms required clearer auto-renewal disclosures, explicit opt-in checkboxes, and easier cancellation buttons. Post-settlement, some complaints persist around pricing opacity and aggressive retention flows, but the company has materially improved its cancellation process. Reddit r/noom communities in 2026 cite repetitive content, low calorie recommendations, and poor coaching personalization as ongoing frustrations, though many users report successful weight loss outcomes. [CU032, CU033, CU034, CU035, CU036, CU037]

6.6 Exhibits

7.1 Market & GLP-1 Disruption Risk

The rise of GLP-1 receptor agonists (semaglutide, tirzepatide) fundamentally reshapes the addressable market for behavioral-only weight-loss apps. Noom's pivot to Noom Med and its GLP-1 Companion attempts to ride this wave rather than be swept aside, but the pivot introduces new dependencies. GLP-1 medications now dominate consumer interest in weight management, with the global market exceeding $50B in 2025 and projected growth to $130B by 2030. Noom's core behavioral subscription — the legacy revenue engine — faces cannibalization from its own GLP-1Rx program and from well-capitalized competitors like Hims & Hers (2.5M subscribers, $2.35B 2025 revenue), Ro, and Found that offer similar telehealth-plus-medication bundles. WeightWatchers' Chapter 11 bankruptcy filing in 2025 illustrates how quickly legacy behavioral models can collapse when GLP-1 alternatives gain traction. A JAMA retrospective study found that 40-50% of GLP-1 patients discontinue within 12 months, creating both a retention opportunity and a risk that Noom's engagement-layer value proposition proves insufficient to prevent churn once medications are paused. If Noom's behavioral differentiation does not demonstrably improve medication adherence and long-term outcomes versus generic telehealth providers, the company's premium pricing and subscription economics are difficult to sustain.[CR001, CR002, CR003, CR004, CR005, CR006]

7.2 Regulatory & Legal Risk

Noom operates at the intersection of three high-enforcement regulatory domains: FTC subscription/negative-option practices, FDA telehealth and compounded drug oversight, and state consumer protection laws. The company settled a $62M class action (Wittels McInturff Palikovic v. Noom Inc., S.D.N.Y., final approval July 2022) over auto-renewal dark patterns, agreeing to business-practice changes including explicit opt-in consent, easier cancellation, and renewal reminders. Though that litigation is resolved, the FTC continues aggressive enforcement under ROSCA and Section 5, and in March 2026 launched a new ANPRM to revive its vacated Click-to-Cancel rule. Noom's subscription model — which still involves multi-month commitments, quarterly billing for GLP-1 programs, and complex cancellation flows — remains exposed to future FTC actions or state AG enforcement in the ~30 states with auto-renewal laws. Separately, the FDA issued 30 warning letters to telehealth companies in March 2026 for misleading marketing of compounded GLP-1 products. Noom Med currently sells compounded semaglutide under Section 503A exceptions, and pharmaphorum reports that Novo Nordisk and Eli Lilly are suing to challenge the compounding framework. If courts or regulators restrict 503A compounding or determine Noom's offerings are "essentially a copy" of approved drugs, the entire Noom Med supply chain is at risk of disruption.[CR007, CR008, CR009, CR010, CR011, CR012]

7.3 Data Privacy & Compliance Risk

As a digital health platform collecting sensitive weight, medication, and behavioral data, Noom is exposed to evolving privacy enforcement. The HHS Office for Civil Rights issued December 2022 guidance (partially vacated June 2024 for unauthenticated pages) clarifying that HIPAA obligations apply when tracking technologies on covered-entity pages transmit protected health information. While Noom itself may not be a HIPAA-covered entity in all contexts, the Meta Pixel class action litigation (John Doe v. Meta Platforms, N.D. Cal.) — now proceeding past dismissal with 664+ hospital systems implicated — demonstrates the industry-wide legal exposure for health platforms using third-party tracking pixels. Legacy Health and Garnet Health both settled pixel-related class actions in February 2026. Noom's own privacy policy (noom.com/about-us) discloses use of analytics and advertising technologies. If Noom Med prescribes medications, it operates closer to covered-entity territory and faces heightened HIPAA compliance obligations. State privacy laws including CCPA/CPRA, the Washington My Health My Data Act, and Connecticut health data statutes independently create litigation surface for digital health companies collecting sensitive health information. Noom's large user base of 50M+ registered users amplifies per-incident exposure in any data breach or improper disclosure scenario.[CR016, CR017, CR018, CR019, CR020, CR021]

7.4 Financial & Business-Model Risk

Noom's financial trajectory shows a post-COVID correction that raises burn, churn, and valuation concerns. Revenue peaked at approximately $400M in 2021 (canonical), with Sacra estimating $1B ARR by 2023 driven by aggressive subscriber growth. However, post-pandemic normalization, coaching quality complaints, and GLP-1 competition have driven subscriber declines from a peak of ~5M paying users to low single-digit millions. The secondary market now values Noom at approximately $720M — a 77%+ discount to the $3.7B Series F peak — implying a revenue multiple under 1x. This valuation compression limits fundraising optionality and makes IPO timing extremely challenging. The GLP-1Rx program reached $100M revenue run-rate within four months of its September 2024 launch, but this new revenue stream carries higher COGS (medication, clinical staff, pharmacy partnerships) than the legacy software subscription. Quarterly billing structures for GLP-1 programs ($199-$299/month billed quarterly) introduce refund and chargeback exposure. High churn remains structural: weight-loss subscription services face 50-70% first-year attrition industry-wide. If GLP-1 revenue growth cannot offset legacy behavioral subscription decline and margin compression, Noom faces a working-capital squeeze that could force additional cost restructuring or a down-round fundraise.[CR023, CR024, CR025, CR026, CR027, CR028]

7.5 Operational, Key-Person & Execution Risk

Noom executed ~20% workforce layoffs in 2022, with MobiHealthNews confirming additional layoffs in 2024-2025 tied to a "revenue mix shift" toward GLP-1 products. Headcount has declined from a peak of ~3,400 to approximately 2,500. This restructuring coincided with a CEO transition in July 2023, when co-founder Saeju Jeong stepped to Executive Chairman and Geoff Cook (former MeetMe/The Meet Group CEO) took the CEO role. The leadership transition introduces execution risk as Noom simultaneously pivots its core business model from behavioral coaching to medication-plus-coaching while managing morale challenges from repeated restructuring. Glassdoor and employee reviews indicate cultural strain from cost-cutting and strategic uncertainty. Key-person risk is moderate: co-founder Artem Petakov remains as President, providing continuity, but the company's public-facing narrative has shifted significantly under new leadership. Operationally, Noom now manages a complex dual-track business — a legacy software subscription (Noom Weight, Noom Mood) alongside a clinical telehealth operation (Noom Med) requiring physician networks, pharmacy partnerships, cold-chain medication logistics, and clinical compliance. This operational complexity creates integration risk, particularly if regulatory changes force rapid adaptation of the GLP-1 supply model.[CR031, CR032, CR033, CR034, CR035, CR036]

7.6 Exhibits

8.1 Valuation History and Resets

Noom's valuation story is one of dramatic peak-to-trough compression. The company raised approximately $643M cumulatively across rounds from seed through Series F. The Series F in May 2021 was the defining liquidity event: $540M raised at a $3.7B post-money valuation, led by Silver Lake with participation from Oak HC/FT, Temasek, Novo Holdings, Sequoia Capital, RRE Ventures, and Samsung Ventures. At the time, Noom's revenue had reportedly reached approximately $400M (FY2020), implying a roughly 9x trailing revenue multiple at the Series F mark. Management reportedly discussed IPO plans at valuations approaching $10B within a year of the raise. The valuation reset has been severe. By mid-2026, secondary-market transactions imply a valuation of approximately $720M — a roughly 77-81% discount to the Series F price. Multiple factors drove this compression: the post-COVID normalization of digital health engagement, aggressive cost cutting and layoffs (approximately 20% of staff in 2022, further restructuring in 2023-2024), FTC scrutiny over subscription dark patterns resulting in a $56M class-action settlement, the competitive disruption from GLP-1 medications (Ozempic, Wegovy, Zepbound) reshaping the weight-loss market, and declining legacy app subscriber counts from a peak of approximately 5M paying subscribers. The Noom SEC Form D filing (CIK 0001595910) confirms the entity was originally incorporated as WorkSmart Labs in Delaware, providing statutory anchoring for the company's capital-raising history. Noom has not filed an S-1 and does not appear on any confirmed 2026 IPO docket, though Forge Global lists it as a "highly anticipated" watchlist candidate with uncertain timing.[CV001, CV002, CV003, CV004, CV005, CV006]

8.2 Secondary-Market Signals

The secondary market provides the most current price discovery for Noom equity. As of April-June 2026, multiple platforms track Noom shares actively. PM Insights reports an implied valuation of approximately $722M based on recent secondary transactions. Notice.co quotes a share price of approximately $11.69, broadly consistent with the $713-722M enterprise value range across platforms. Caplight similarly lists Noom with active funding round data and comparable company overlays. Forge Global shows active bids and asks with $272M in secondary market activity over the most recent 90-day window, indicating meaningful institutional interest at these reduced levels despite the steep discount. The ~77% discount from the Series F is severe but not unprecedented for 2021-vintage growth rounds. The implied revenue multiple at secondary levels depends heavily on current revenue estimates: if Noom's revenue has stabilized at approximately $500M+ (accounting for the GLP-1 Rx ramp offsetting legacy subscriber attrition), the secondary mark implies a sub-1.5x revenue multiple. If revenue has fallen below $400M due to faster-than-expected legacy churn, the multiple could be closer to 1.8-2.0x. This ambiguity is itself a key valuation issue: Noom remains private and has not disclosed audited financials, making revenue estimation inherently uncertain and forcing secondary buyers to price on incomplete information. The contrast between Sacra's estimate of $1B ARR in 2023 (growing 25% YoY) and the steep valuation discount suggests the market is pricing execution risk and competitive disruption rather than a pure revenue collapse.[CV010, CV011, CV012, CV013, CV014, CV015]

8.3 Comparable-Company and Multiple Analysis

The public comparable set for Noom spans telehealth, consumer digital health, and weight-loss companies. Hims & Hers Health (NYSE: HIMS) is the most relevant public analog as a D2C telehealth platform with major GLP-1 exposure. HIMS trades at approximately $6.2-7.4B market cap on $2.8-3.0B guided 2026 revenue, implying a P/S ratio of approximately 2.6-3.2x on a trailing basis. HIMS demonstrates what premium multiples look like for a high-growth consumer health platform with direct GLP-1 revenue. Omada Health (NASDAQ: OMDA), which IPO'd in June 2025, reported Q1 2026 revenue of $78M (42% YoY growth) and trades at approximately $1.03B market cap with a P/S of roughly 3.6x on forward revenue guidance of $322-330M. Omada represents the B2B digital health comp with employer/payer distribution analogous to Noom for Work. Teladoc Health (NYSE: TDOC) trades at a deeply discounted P/S of approximately 0.55x on ~$2.5B revenue, reflecting flat-to-declining growth and the market's severe punishment of post-COVID telehealth platforms. WeightWatchers (WW) emerged from Chapter 11 bankruptcy in June 2025 after eliminating $1.15B of debt, with Q4 2025 revenue of $163M (down 12% YoY) and clinical revenue growing 32% — the closest analog for what legacy behavioral weight-loss looks like during GLP-1 disruption. The Noom secondary-market implied multiple of ~1.0-1.5x revenue sits between the Teladoc discount floor and the Omada/HIMS growth premium, consistent with a business facing near-term headwinds but with upside optionality from Noom Med.[CV017, CV018, CV019, CV020, CV021, CV022]

8.4 Scenario Valuation Bands

The bear case values Noom at approximately $400-600M. This scenario assumes legacy subscription revenue continues its decline to below $300M annually, Noom Med's GLP-1 revenue stalls at sub-$150M as FDA enforcement on compounded GLP-1s and branded competition from Lilly/Novo squeezes margins, and the company burns cash without reaching profitability. At 1.0-1.5x revenue on a $300-400M revenue base, the implied value sits meaningfully below the current secondary mark and would represent a further 20-45% downside from today's ~$720M implied level. This scenario also incorporates multiple compression toward the Teladoc/WW valuation band. The base case values Noom at approximately $700M-1.1B. This assumes revenue stabilizes at $500-600M driven by the GLP-1 program reaching $200-300M in annualized revenue (consistent with the disclosed $100M run-rate within four months of launch, extrapolated with moderate growth), partial offset of legacy subscriber attrition, and cost restructuring achieving near-breakeven EBITDA. A 1.5-2.0x multiple on $500-600M revenue yields the range. The bull case reaches $1.5-2.5B and requires Noom Med to scale aggressively to $500M+ in revenue (leveraging partnerships with five of the top 20 US health plans), the Noom Weight legacy base to stabilize, successful B2B2C enterprise expansion, and eventual IPO readiness. At 2.5-3.5x on $600-800M revenue, this scenario would imply 100-250% upside from current secondary levels and approach the multiples commanded by HIMS and Omada.[CV027, CV028, CV029, CV030, CV031, CV032]

8.5 Investor Returns, Exit Readiness, and Re-rating Path

For Series F investors who entered at the $3.7B valuation, the current ~$720M secondary implied value represents approximately 81% unrealized loss before accounting for liquidation preferences and secondary transaction discounts. Silver Lake's $540M investment now implies roughly $105M in common-equivalent value (though preference stack details are not publicly disclosed and likely provide some downside protection). Earlier-stage investors fare better: Series E investors at the 2019 valuation likely still carry modest positive returns, and seed/Series A-C investors retain significant multiples on invested capital despite the markdown. The path to re-rating depends primarily on the GLP-1 revenue trajectory. If Noom Med demonstrates sustained growth from its $100M run-rate (disclosed February 2025) toward $300-500M in annual revenue, combined with evidence of strong unit economics and subscriber retention, the market would likely rerate Noom toward the Omada/HIMS multiple band of 2.5-3.5x. IPO readiness requires demonstrating revenue growth reacceleration, margin expansion, and reduced regulatory risk from FTC subscription enforcement and FDA compounding scrutiny. The thesis-break triggers are measurable: continued revenue decline below $400M, GLP-1 program stalling or regulatory forced withdrawal of compounded medications, inability to demonstrate path to profitability, or another round of material layoffs indicating structural rather than cyclical distress. The recommendation is to track rather than invest at current levels: the secondary mark looks roughly fair given uncertainty, but does not offer sufficient margin of safety without better visibility into audited financials and GLP-1 revenue sustainability.[CV034, CV035, CV037, CV038, CV039, CV040]

8.6 Exhibits